1) Early screening and diagnosis of Alzheimer's disease (AD): Detecting peripheral blood biomarkers can identify corresponding pathological changes before clinical symptoms manifest, thereby aiding in the early screening of AD and providing an opportunity for timely intervention;
2) Assessment related to AD treatment: Following targeted drug therapy or other related treatments, the combined detection of peripheral blood biomarkers allows for dynamic monitoring of the treatment's effectiveness and prognosis in AD patients;
3) Primary healthcare: Combined with health checkups, elderly individuals can undergo regular annual screening and receive early intervention.
